Affordable Prescription Drugs Act
Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.
Requires any person engaged in the manufacture and sale of any new drug or new animal drug approved under the Federal Food, Drug, and Cosmetic Act, for which a patent is still in effect, to report annually to Congress an audit of all financial information relevant to that drug's pricing nationally and internationally, including research and development costs, sufficient to assess the reasonableness of that pricing. Requires disqualification from participation in Federal programs as a penalty for noncompliance with this reporting requirement.
Sponsor introductory remarks on measure. (CR H1127)
- Introduced in House Formatted Text PDF
Cite this page
U.S. Congress. (2026). H.R. 2927: Affordable Prescription Drugs Act. 106th Congress. Open America. https://openamerica.io/bill/106-HR-2927/
"H.R. 2927: Affordable Prescription Drugs Act." 106th Congress, 2026, Open America, https://openamerica.io/bill/106-HR-2927/.
H.R. 2927, 106th Cong. (2026), https://openamerica.io/bill/106-HR-2927/.
[H.R. 2927: Affordable Prescription Drugs Act](https://openamerica.io/bill/106-HR-2927/)